AAIC 2026 data show subcutaneous LEQEMBI delivers bioequivalent efficacy and safety to IV therapy, offering a convenient once‑weekly autoinjector option for early Alzheimer’s disease
Written By: Anshu Gupta, PharmD
Reviewed By: Pharmacally Editorial Team
Eisai and Biogen presented new data at the Alzheimer’s Association International Conference (AAIC) 2026 showing that the subcutaneous autoinjector (SC-AI) formulation of LEQEMBI (lecanemab) achieved efficacy and safety comparable to the approved intravenous (IV) regimen in people with early Alzheimer’s disease. The findings support a more convenient treatment pathway that could reduce reliance on infusion centers while maintaining long-term therapy.
LEQEMBI is an anti-amyloid beta monoclonal antibody approved for early Alzheimer’s disease. The SC autoinjector was developed as a fixed-dose alternative to IV infusion, offering the potential for more convenient long-term treatment, including home administration for appropriate patients.
Clinical Data Support Bioequivalence and Comparable Outcomes
The AAIC presentation combined pharmacokinetic, pharmacodynamic, efficacy, safety, immunogenicity, and real-world data from the LEQEMBI SC development program. The analyses were not linked to a single ClinicalTrials.gov registration, and Eisai has not yet announced regulatory submission timelines for the SC formulation.
Pharmacokinetic analyses showed that a once-weekly fixed 500 mg SC dose achieved bioequivalent exposure to the approved 10 mg/kg IV regimen administered every two weeks. The exposure ratio was 104% (90% confidence interval [CI], 99.1%-109%), meeting established bioequivalence criteria.
Investigators emphasized that lecanemab’s clinical benefit is driven by systemic drug exposure rather than the route of administration. The SC regimen produced drug exposure comparable to IV therapy, supporting similar amyloid plaque clearance, clinical efficacy measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB), and a comparable incidence of amyloid-related imaging abnormalities with edema (ARIA-E). Drug exposure also remained consistent across body weight groups, supporting the use of a fixed-dose regimen without weight-based adjustments.
Safety Findings Remain Consistent with IV Therapy
The overall safety profile of SC LEQEMBI was consistent with the approved IV formulation. Predicted ARIA-E incidence was similar between treatment approaches, while injection-site reactions were generally mild and localized. Systemic injection-related reactions were uncommon.
Immunogenicity remained low, with anti-drug antibodies detected in 1.4% of patients receiving the 500 mg SC regimen. No neutralizing antibodies were identified.
Real-World Experience Supports Long-Term Use
Real-world data from two U.S. Alzheimer’s treatment centers reinforced the clinical findings. At the Alzheimer’s Research and Treatment Center, 28 patients receiving SC LEQEMBI demonstrated slower cognitive decline over 36 months than a matched Alzheimer’s Disease Neuroimaging Initiative (ADNI) natural history cohort. The group included 25 patients who initiated SC therapy and 3 patients who transitioned from IV treatment.
At First Choice Neurology and Visionary Investigators Network, 10 of 11 evaluable patients (91%) remained stable or improved on Mini-Mental State Examination (MMSE) scores after at least six months of SC maintenance therapy.
Patient and caregiver surveys also indicated favorable treatment experience. Satisfaction ranged from 75% to 97%, convenience ratings from 83% to 97%, and 92% to 100% of respondents said they would recommend the treatment. The survey sample sizes were not disclosed.
Flexible Treatment Pathway
Patients may transition between IV and SC administration during treatment and missed SC doses can be administered the following day or up to six days later without restarting therapy.
Together, the AAIC 2026 findings support the subcutaneous autoinjector as a flexible long-term treatment option that preserves the efficacy and safety of IV LEQEMBI while improving treatment convenience. Eisai continues to lead the global development and regulatory strategy for lecanemab in collaboration with Biogen, with future regulatory updates expected as development of the SC formulation progresses.
What This Means for Patients
The new findings suggest that people with early Alzheimer’s disease may eventually have the option to receive LEQEMBI as a once-weekly subcutaneous injection instead of an intravenous infusion, while maintaining similar effectiveness and safety. A more convenient treatment option could reduce visits to infusion centers, make long-term therapy easier for patients and caregivers, and improve access to disease-modifying treatment. However, the subcutaneous formulation is still under clinical development, and patients should continue using LEQEMBI only as approved by their healthcare provider until regulatory authorities authorize this new administration option.
Reference
About the Writer
Anshu Gupta (LinkedIn) is a PharmD professional and healthcare writer with interests in clinical research, pharmacovigilance, regulatory affairs, and medical writing. She has presented research at academic conferences and completed certifications in Good Clinical Practice (GCP), ICH-GCP, and drug safety. Passionate about clinical trials and evidence-based medicine, she is committed to translating scientific evidence into accurate, reliable, and accessible healthcare content.